A leader in the success game: Editas Medicine Inc (EDIT) Stock

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]

Editas Medicine Inc (EDIT) Stock is Just Right Size-Neither Too Big Nor Too Small

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]

Does Editas Medicine Inc (EDIT) Stock have plenty of room for growth?

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]

It’s not the right time to quit: Editas Medicine Inc (EDIT) Stock

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]

Is Editas Medicine Inc (EDIT) Stock a good investment?

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]

Are Options A Good Investment Right Now? Editas Medicine Inc (EDIT) Stock

Citigroup raised the price target for the Editas Medicine Inc (NASDAQ:EDIT) stock from “a Neutral” to “a Buy”. The rating was released on October 24, 2023, according to finviz. The stock was upgraded by Stifel, who disclosed in a research note on September 29, 2023, from Hold to Buy and set the price objective to […]